RXDX — Prometheus Biosciences Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeLarge Cap
- $9.56bn
- $8.85bn
- $6.81m
U.S. RESEARCH ROUNDUP-C4 Therapeutics, Crowdstrike Holdings, Signify Health
Brief: Prometheus Biosciences Posts Q4 Revenue $1.0 Mln
U.S. STOCKS ON THE MOVE-Tesla, McDonald's, Wolfspeed
Guggenheim sees opportunities within neurology, immunology spaces in 2022
Prometheus soars to 6-month high as Oppenheimer upgrades stock
U.S. RESEARCH ROUNDUP-Elastic, Prometheus Biosciences, Stitch Fix
Brief: Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications
U.S. RESEARCH ROUNDUP-IBM, Prometheus Biosciences, Shift Technologies
Brief: Prometheus Biosciences Says Board Has Appointed Mark Mckenna To Succeed Tadataka Yamada As Chairman
Brief: Prometheus Biosciences Posts Qtrly Loss Per Share $0.49
Prometheus Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Prometheus Biosciences Says Chairman Of Board, Tadataka Yamada, Passed Away Unexpectedly
Brief: Prometheus Biosciences Announced Initiation Of Apollo-Cd Phase 2A Clinical Trial Evaluating Pra023 For Moderate-To-Severe Crohn's Disease
Brief: Prometheus Announces Initiation Of Global Phase 2 Clinical Trial Of PRA023 In Ulcerative Colitis
Brief: Prometheus Biosciences Achieves Milestone Payment From Dr. Falk Pharma GmbH Further Validating The Prometheus360™ Platform
Prometheus Biosciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Prometheus Biosciences Posts Quarterly Loss Per Share Of $1.67
Prometheus Biosciences: Jumps in Nasdaq debut
Brief: Prometheus Biosciences Shares Open 31.3% Above IPO Price In Debut On Nasdaq